RGRobert Maximilian Genta

Robert Maximilian Genta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert Maximilian Genta has a total of 216 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colonic Mast Cell Density and Diarrhoea: Evidence Against a Threshold Effect in Biopsies From 3508 Patients

    by Marlena Langreiter, Robert M. Genta, Philipp Schreiner

    Background: Elevated mast cell (MC) counts in colonic biopsies are frequently observed in patients with chronic diarrhoea or unspecific abdominal symptoms, potentially leading to a diagnosis of mast cell activation syndrome. However, the clinical relevance of MC quantification in this setting remains controversial. Aim: This study aimed to determine the proportion of patients with elevated MC counts who presented with diarrhoea compared to those with normal counts. As a secondary endpoint, we assessed how often MC quantification was performed and what the underlying clinical indications were. Methods: We analysed a large US national pathology database with 3.3 million colonoscopies performed between January 2009 and December 2023. Screening colonoscopies for colon cancer detection were excluded. For patients with multiple colonoscopies, only the first procedure was included. This resulted in a total of 2,059,147 colonoscopies. Results: Colonic mast cells were evaluated in 3508 reports (0.17%). In 1167 cases the report contained either the expressions indicating increased MC, or a MC count > 20 MC/high power field (hpf). Diarrhoea was present in 58.3%, 54.1%, 54.7%, 50.0% and 33.3% of patients with MC count of < 20/hpf, 20–39/hpf, 40–59/hpf, 60–98/hpf and ≥ 99/hpf, respectively. Conclusion: These data do not show a relationship between diarrhoea and elevated MC in the colonic mucosa. Therefore, we suggest that the incorporation of MC quantification into the histologic evaluation of colonoscopic biopsies obtained for common GI indications may not be warranted.

  • Open Access

    Autoimmune gastritides: A critical review

    by Massimo Rugge, Robert M. Genta, David Y. Graham

  • Open Access

    Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System

    by Massimo Rugge, Marta Sbaraglia, Giulia Fiorini, Gavino Faa, Robert M Genta

    Gastric mucosa atrophy is the cancerization field for gastric cancer development. Atrophic changes in the gastric mucosa can be assessed endoscopically and histologically. Gastric serology (e.g., pepsinogens and their ratio, and gastrin) may provide information on the functional status of the mucosa. However, outside large-scale epidemiological studies, the clinical reliability of serology at the individual patient level remains controversial. Histology-based estimates of atrophy-associated neoplastic risk require mucosal specimens from both the antral/mucus-secreting and corpus/fundus oxyntic compartments. Inspired by the clinical–biological framework of cancer staging, the Operative Link on Gastritis Assessment (OLGA) staging system classifies the severity and topography of mucosal atrophy into five stages, ranging from 0 to IV. International trials have validated the stepwise increasing risk of cancer with disease progression. Based on this evidence, OLGA stages are classified into low-risk (0–I) and high-risk (III–IV), with stage II remaining clinically controversial. The prevalence of high-risk stages varies according to patient- and population-specific risk factors. Among these, the most significant is the prevalence of Helicobacter pylori, a recognized oncogenic agent. Bacterial infection at the time of the initial endoscopy requires eradication therapy regardless of the stage of gastritis. Histological stage reliably identifies the endoscopic population at a high risk of cancer progression and shapes the schedule of endoscopy/histology-based surveillance. Serology at the index endoscopy may circumvent the inherent inconsistencies of population-based studies. This patient-specific serology could serve as an interval for non-invasive monitoring within the endoscopy/histology follow-up framework.

  • Open Access

    Lichenoid Esophagitis: A Clinicopathological Comparison with Lymphocytic and Eosinophilic Esophagitis

    by Salima Haque, S. Maral K Mohammadi, Anuradha Singhal, Amnon Sonnenberg, Robert Maximilian Genta, Massimo Rugge

    Background and Aims: Lichenoid esophagitis (LichE) is rarely encountered by gastrointestinal endoscopists. Using a large nationwide database of clinicopathological records, the demographic and clinical characteristics of patients with LichE were compared to patients with lymphocytic esophagitis (LyE) and eosinophilic esophagitis (EoE). Methods: In a case-control study, cases with a diagnosis of LichE, LyE, or EoE were compared to a control population of all patients without these 3 conditions. In addition to histopathology, patients’ demographics, clinical presentation, and gastrointestinal comorbidities were considered. Statistical significance was assessed using odds ratios (OR) and 95% confidence intervals (95%CI). Results: Among 967,773 unique patients with esophageal biopsies, LichE was found in 511 (0.05%), LyE in 1,786 (0.18%), EoE in 56,474 (5.84%), and none of these 3 diagnoses in a control population of 909,002 patients. LichE patients were significantly older, and EoE patients were significantly younger than the control population (p<0.0001). LichE and LyE significantly prevailed in females (OR=1.69; 95%CI: 1.40-2.04 and 1.34; 1.22-1.47, respectively). EoE was significantly less common in females (OR=0.49; 95%CI: 0.48-0.49). All 3 types of esophagitis were significantly less common among Hispanics, with their respective ORs of 0.70 (95%CI: 0.50-0.98), 0.83 (95%CI: 0.70-0.98), and 0.55 (95%CI: 0.53-0.57). EoE was also less common in persons of East and South Asian ancestry, with respective ORs of 0.52 (95%CI: 0.47-0.56) and 0.66 (95%CI: 0.56-0.76). Conclusions: Increasing clinical awareness of LichE may enhance its clinico-pathological recognition, clarify its natural history, and ultimately lead to more effective clinical management.


  • Open Access

    The Landscape of Helicobacter pylori-related Gastric Carcinogenesis

    by Paulo Pimentel de Assumpção, Robert M Genta, Maria Constanza Camargo, Jessica Manoelli Costa da Silva, Manuel Ricardo Amieva, Massimo Rugge

    The relationship between Helicobacter pylori (H. pylori) and humans remains a complex enigma. While other factors contribute to gastric cancer (GC), their impact pales in comparison to the central role of H. pylori. Various cofactors, such as dietary carcinogens and Epstein-Barr virus infection, can lead to GC independently of H. pylori. However, it is likely the combination of mechanisms, especially those driven by H. pylori, that represents the primary force behind GC development. Identifying individuals at high risk of developing H. pylori-related GC or detecting the disease in its earliest stages remains a significant challenge. To address this, we aim to refine the existing gastric carcinogenic model by incorporating molecular data, oncological concepts common to many cancers, and data from innovative experimental approaches. This updated model, applicable to both intestinal and diffuse GC, builds on Pelayo Correa's carcinogenesis pathway while expanding our understanding of H. pylori's role in gastric carcinogenesis. It not only emphasizes the direct cellular effects of H. pylori virulence factors but also integrates underrecognized carcinogenic mechanisms, including the interactions between H. pylori and stem cells, providing a more comprehensive view of H. pylori's contribution. By acknowledging additional molecular drivers in GC and recognizing H. pylori's potential involvement in these processes, this model could offer more precise interpretations of GC development and open new avenues for clinical interventions.


  • Top Cited Papers
    Open Access

    RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates

    by Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Y Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, et al.

    At the end of the last century, a far-sighted ‘working party’ held in Sydney, Australia addressed the clinicopathological issues related to gastric inflammatory diseases. A few years later, an international conference held in Houston, Texas, USA critically updated the seminal Sydney classification. In line with these initiatives, Kyoto Global Consensus Report, flanked by the Maastricht-Florence conferences, added new clinical evidence to the gastritis clinicopathological puzzle. The most relevant topics related to the gastric inflammatory diseases have been addressed by the Real-world Gastritis Initiative (RE.GA.IN.), from disease definitions to the clinical diagnosis and prognosis. This paper reports the conclusions of the RE.GA.IN. consensus process, which culminated in Venice in November 2022 after more than 8 months of intense global scientific deliberations. A forum of gastritis scholars from five continents participated in the multidisciplinary RE.GA.IN. consensus. After lively debates on the most controversial aspects of the gastritis spectrum, the RE.GA.IN. Faculty amalgamated complementary knowledge to distil patient-centred, evidence-based statements to assist health professionals in their real-world clinical practice. The sections of this report focus on: the epidemiology of gastritis; Helicobacter pylori as dominant aetiology of environmental gastritis and as the most important determinant of the gastric oncogenetic field; the evolving knowledge on gastric autoimmunity; the clinicopathological relevance of gastric microbiota; the new diagnostic horizons of endoscopy; and the clinical priority of histologically reporting gastritis in terms of staging. The ultimate goal of RE.GA.IN. was and remains the promotion of further improvement in the clinical management of patients with gastritis.


  • Open Access

    Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Studies

    by Evan S. Dellon, Enoch Bortey, Alan T. Chang, Craig A. Paterson, Kevin Turner, Robert M. Genta

    INTRODUCTION: Consensus is lacking regarding the number of eosinophils (eos) required for the diagnosis of eosinophilic gastritis (EoG) and eosinophilic duodenitis (EoD). In addition, thresholds that require multiple high-power fields (HPFs) may not be practical for clinical use, resulting in delayed or missed diagnoses. This pooled analysis of 4 prospective studies assessed thresholds for multiple and single HPFs used to diagnose EoG and EoD. METHODS: Studies included the phase 2 ENIGMA1, the phase 3 ENIGMA2, an EoG/EoD prevalence study and a healthy volunteer study. Eos were quantified in the epithelium and lamina propria for controls and symptomatic participants. Symptomatic participants were further divided by histologic diagnosis of EoG/EoD. Peak eos counts were assessed, and the area under the receiver operating characteristic curve was analyzed to identify eos cutoffs for detection of EoG/EoD using the Youden index and sensitivity and specificity equality approaches. RESULTS: Based on the highest specificity analysis in 740 patients, the optimal eos threshold was determined to be 20 eos/HPF in 5 gastric HPFs for EoG (71% sensitivity and 94% specificity) and 33 eos/HPF in 3 duodenal HPFs for EoD (49% sensitivity and 100% specificity). For single-field analysis, the optimal eos thresholds were 33 eos/HPF (EoG) and 37 eos/HPF (EoD), both corresponding to 93% sensitivity and 93% specificity. DISCUSSION: Highly specific single gastric and duodenal HPF thresholds may have more clinical applicability than thresholds requiring multiple HPFs and could better facilitate development of practical histopathologic guidelines to aid pathologists and clinicians in the detection and diagnosis of EoG and/or EoD.


  • Open Access

    Quantification of Mucosal Mast Cells in the Gastrointestinal Tract: A Primer for Practicing Pathologists

    by Robert M. Genta, Kevin O. Turner, Margaret H. Collins, Joshua B. Wechsler, Nicoleta C. Arva, Maria A. Pletneva, Evan S. Dellon, Marjorie M. Walker

    Context.—: Mast cells are essential components of the immune system and play crucial pathogenetic roles in several digestive diseases, including mastocytic enterocolitis and eosinophilic gastrointestinal disorders. Pathologists have rarely been asked to evaluate the distribution and density of mast cells in gastrointestinal (GI) biopsy specimens. However, such requests are becoming more common because of an increasing awareness of the role of mast cells in functional GI disease and in both esophageal and nonesophageal eosinophilic gastrointestinal disorders. Objective.—: To provide pathologists with tools to incorporate the assessment of mast cells in the evaluation of esophageal, gastric, and intestinal specimens by developing a systematic approach to their evaluation, counting, and reporting. Design.—: This study consisted of a review of the literature followed by multiple consensus sessions to decide where to count mast cells and what a countable mast cell is. Results.—: We reviewed 135 papers addressing the content of mast cells in the digestive tract, selected 21 that detailed how cells were counted (microscope lens, area of high-power fields, locations evaluated, type of cells considered as countable), and summarized their data in a table. Then, drawing from both the acceptable literature and our own extensive experience, we reached a tentative consensus on: (1) the normal numbers in the different segments of the GI tract; (2) the morphology of countable mast cells; and (3) the locations and strategies for counting them. Conclusions.—: The result is a set of suggestions for reporting mast cell counts, their distribution, and their location in a way clinicians can understand and use for management decisions.